Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index; 16 of the 61 sources its claims cite were checked for support.

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis

Open access

Abstract

Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis (NASH) and fibrosis. Although various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, the response rate and efficacies in clinical trials were not optimum. Here we report that prophylactic but not therapeutic administration of obeticholic acid (OCA) prevents hepatic stellate cell (HSC) activation and fibrogenesis. Activated HSCs show limited response to OCA and other FXR agonists due to enhanced FXR SUMOylation. SUMOylation inhibitors rescue FXR signaling and thereby increasing the efficacy of OCA against HSC activation and fibrosis. FXR upregulates Perilipin-1, a direct target gene of FXR, to stabilize lipid droplets and thereby prevent HSC activation. Therapeutic coadministration of OCA and SUMOylation inhibitors drastically impedes liver fibrosis induced by CCl 4, bile duct ligation, and more importantly NASH. In conclusion, we propose a promising therapeutic approach by combining SUMOylation inhibitors and FXR agonists for liver fibrosis.

Overview

CoChat Summary

TL;DR

In mouse models of CCl₄-, bile duct ligation-, and NASH-induced liver fibrosis, prophylactic but not therapeutic obeticholic acid (OCA) prevents hepatic stellate cell (HSC) activation and fibrogenesis, while activated HSCs show enhanced FXR SUMOylation that limits FXR agonist response. Combining SUMOylation inhibitors with OCA restores FXR signaling, upregulates the direct FXR target Plin1, stabilizes lipid droplets, and reduces fibrosis.

Key findings

  • In the phase III NASH trial cited, liver fibrosis improvement occurred in 18% of patients on 10 mg OCA and 23% on 25 mg OCA versus 12% on placebo; the paper uses this modest response rate to motivate combination therapy.
  • Prophylactic OCA reduced serum ALT and fibrosis in CCl₄- and BDL-induced models, whereas therapeutic OCA showed marginal effects; similarly, prophylactic but not therapeutic OCA reduced ALT/AST and fibrosis in HFHC and MCD NASH models (n = 6 biological independent samples per experiment).
  • OCA was effective in quiescent but not activated HSCs; activated HSCs from CCl₄-treated, BDL-operated, and NASH patients had elevated FXR SUMOylation, mainly via SUMO1 at Lys122, Lys275, and Glu277, and a triple SUMO-site mutant FXR was resistant to SUMOylation-caused loss of transcriptional activity.
  • SUMOylation inhibitors SP and GA inhibited FXR SUMOylation; SP restored OCA-induced Shp expression and anti-fibrotic effects in activated HSCs, and OCA plus SP reduced fibrosis in CCl₄, BDL, HFHC, and MCD models. Plin1 was identified as a direct FXR target gene; Plin1 overexpression increased lipid content and decreased pro-fibrotic genes, while Plin1 knockdown abolished OCA-mediated lipid storage and suppression of pro-fibrotic markers.

Methods

  • Male C57BL/6J mice (8 weeks old, ~20 g) were used for CCl₄ (20% CCl₄/mineral oil, 5 ml/kg i.p., three times per week for 4 weeks), BDL, HFHC diet for 16 weeks, and MCD diet for 6 weeks. OCA was given at 1.5 or 5 mg/kg in prophylactic versus therapeutic arms; SP was injected subcutaneously at 200 mg/kg/day.
  • Primary murine HSCs were isolated by pronase–collagenase perfusion and density gradient centrifugation; HSC-T6, AML12, and primary human HSCs from healthy donors or NASH patients were also used. Treatments included OCA, GW4064, or WAY-362450 at 5 μM, GA at 50 μM, and SP at 5 μM.
  • Main analyses included serum ALT/AST, H&E/Masson/Sirius red histology, RT-PCR, western blot, Co-IP, in vivo SUMOylation assays, biolayer interferometry, luciferase reporter assays, ChIP, and cellular lipid staining/quantification. Statistics used mean ± SEM with two-tailed Student’s t-test or one-way ANOVA with Tukey post hoc analysis; P < 0.05 was significant.

Limitations

  • The paper does not state limitations explicitly.
  • Evident from the text: efficacy data are preclinical, using rodent fibrosis models and cultured HSCs, with no clinical trial of OCA plus a SUMOylation inhibitor; human HSCs were commercially obtained from healthy donors or NASH patients and used at passages 2–5.
  • Evident from the text: in vivo synergy was demonstrated with SP plus OCA, whereas GA plus OCA was shown mainly in cell-based assays; animal experiments used male C57BL/6J mice only.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-019-14138-6

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Prophylactic but not therapeutic administration of OCA alleviates liver fibrosis. The anti-fibrotic effects of prophylactic and therapeutic administration of OCA were evaluated in CCl4-induced a–d or BDL-induced e–h liver fibrosis models. a and e Mouse experiment procedure schemes. b and f Serum ALT and AST levels. c and g H&E, Masson and Sirius red staining of liver sections. Data are representative of n = 6 biological independent samples. Scale bar, 100 μm. d and h Levels of Acta2, Tgfb1, Col1a1, and Col1a2 mRNAs in liver. n = 6 biologically independent samples within these experiments. Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.
Fig. 1 Prophylactic but not therapeutic administration of OCA alleviates liver fibrosis. The anti-fibrotic effects of prophylactic and therapeutic administration of OCA were evaluated in CCl4-induced a–d or BDL-induced e–h liver fibrosis models. a and e Mouse experiment procedure schemes. b and f Serum ALT and AST levels. c and g H&E, Masson and Sirius red staining of liver sections. Data are representative of n = 6 biological independent samples. Scale bar, 100 μm. d and h Levels of Acta2, Tgfb1, Col1a1, and Col1a2 mRNAs in liver. n = 6 biologically independent samples within these experiments. Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.CC BY · PubMed Central
Fig. 2 Prophylactic but not therapeutic OCA administration cures NASH-induced fibrosis. The effects of prophylactic and therapeutic administration of OCA were evaluated in NASH-induced fibrosis models caused by HFHC a–d and MCD e–h diet. a and e Mouse experiment procedure schemes. b and f Serum ALT and AST levels. c and g H&E, Masson and Sirius red staining of liver sections. Data are representative of n = 6 biological independent samples. Scale bar, 100 μm. d and h Levels of Acta2, Tgfb1, Col1a1, and Col1a2 mRNAs in liver. n = 6 biologically independent samples within these experiments. Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.
Fig. 2 Prophylactic but not therapeutic OCA administration cures NASH-induced fibrosis. The effects of prophylactic and therapeutic administration of OCA were evaluated in NASH-induced fibrosis models caused by HFHC a–d and MCD e–h diet. a and e Mouse experiment procedure schemes. b and f Serum ALT and AST levels. c and g H&E, Masson and Sirius red staining of liver sections. Data are representative of n = 6 biological independent samples. Scale bar, 100 μm. d and h Levels of Acta2, Tgfb1, Col1a1, and Col1a2 mRNAs in liver. n = 6 biologically independent samples within these experiments. Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.CC BY · PubMed Central
Fig. 3 OCA is ineffective against already activated HSCs. Effect of OCA on HSC activation were compared between quiescent and activated HSCs, caused by CCl4 treatment a–c or BDL operation d–f. Freshly isolated HSCs were treated with OCA starting 1 day after seeding and collected for analysis after 4 days in culture. a and d mRNA levels of Acta2, Col1a1, Col1a2, and Tgfb1 mRNAs in primary HSCs. b and e Lipids quantitation. c and f αSMA, Bodipy and Nile red staining of HSCs, data are representative of n = 3 biological independent samples. Scale bar, 50 μm. n = 3 biologically independent samples within these experiments. Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.
Fig. 3 OCA is ineffective against already activated HSCs. Effect of OCA on HSC activation were compared between quiescent and activated HSCs, caused by CCl4 treatment a–c or BDL operation d–f. Freshly isolated HSCs were treated with OCA starting 1 day after seeding and collected for analysis after 4 days in culture. a and d mRNA levels of Acta2, Col1a1, Col1a2, and Tgfb1 mRNAs in primary HSCs. b and e Lipids quantitation. c and f αSMA, Bodipy and Nile red staining of HSCs, data are representative of n = 3 biological independent samples. Scale bar, 50 μm. n = 3 biologically independent samples within these experiments. Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.CC BY · PubMed Central
Fig. 4 Elevated SUMOylation of FXR in activated HSCs represses its transcriptional activity. a OCA failed to induce the expression of SHP in activated HSCs, caused by CCl4 treatment, BDL operation, and from NASH patients. b SUMOylation of FXR elevated in activated HSCs, caused by CCl4 treatment, BDL operation, and from NASH patients, as analyzed by Protein SUMOylation Assay Ultra Kit. c, d Shp mRNA levels c and FXR SUMOylation d in cells transfected with SUMO1 plasmid. e, f Shp levels e and FXR SUMOylation f in cells transfected with WT or SUMO-site mutant FXR plasmid together with SUMO1 plasmid (n = 3 biologically independent samples within these experiments). Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with Student’s t-test or ANOVA.
Fig. 4 Elevated SUMOylation of FXR in activated HSCs represses its transcriptional activity. a OCA failed to induce the expression of SHP in activated HSCs, caused by CCl4 treatment, BDL operation, and from NASH patients. b SUMOylation of FXR elevated in activated HSCs, caused by CCl4 treatment, BDL operation, and from NASH patients, as analyzed by Protein SUMOylation Assay Ultra Kit. c, d Shp mRNA levels c and FXR SUMOylation d in cells transfected with SUMO1 plasmid. e, f Shp levels e and FXR SUMOylation f in cells transfected with WT or SUMO-site mutant FXR plasmid together with SUMO1 plasmid (n = 3 biologically independent samples within these experiments). Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with Student’s t-test or ANOVA.CC BY · PubMed Central
Fig. 5 SUMOylation inhibition restores FXR transactivity and inhibits HSC activation. a, b SP and GA significantly inhibit FXR SUMOylation in activated HSCs by Protein SUMOylation Assay Ultra Kit (n = 4 biologically independent samples) a and Co-IP assay (representative of n = 3 biologically independent samples) b. c SP treatment restored the transcriptional activity of FXR. Activated HSCs were treated with OCA in the presence or absence of SP. Fxr and Shp mRNA levels (n = 4 biologically independent samples). d–f SP treatment restored the benefits of OCA in precluding HSC activation. Activated HSCs were treated with OCA in the presence or absence of SP. Lipid quantitation analysis (n = 3 biologically independent samples) d, pro-fibrotic gene mRNA levels (n = 4 biologically independent samples) e, and αSMA, Bodipy, and Nile red staining of HSCs (representative of n = 3 biologically independent samples. Scale bar, 50 μm). f Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.
Fig. 5 SUMOylation inhibition restores FXR transactivity and inhibits HSC activation. a, b SP and GA significantly inhibit FXR SUMOylation in activated HSCs by Protein SUMOylation Assay Ultra Kit (n = 4 biologically independent samples) a and Co-IP assay (representative of n = 3 biologically independent samples) b. c SP treatment restored the transcriptional activity of FXR. Activated HSCs were treated with OCA in the presence or absence of SP. Fxr and Shp mRNA levels (n = 4 biologically independent samples). d–f SP treatment restored the benefits of OCA in precluding HSC activation. Activated HSCs were treated with OCA in the presence or absence of SP. Lipid quantitation analysis (n = 3 biologically independent samples) d, pro-fibrotic gene mRNA levels (n = 4 biologically independent samples) e, and αSMA, Bodipy, and Nile red staining of HSCs (representative of n = 3 biologically independent samples. Scale bar, 50 μm). f Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.CC BY · PubMed Central
Fig. 6 SUMOylation inhibition restores the anti-fibrotic activity of OCA. Fibrotic mice, developed by CCl4 treatment a–d or BDL operation e–h, were treated with OCA in the presence or absence of SP. n = 6 biologically independent samples within these experiments. a and e Mouse experiment procedure schemes. b and f Serum ALT and AST levels. c and g H&E, Masson, and Sirius red staining of liver sections (representative of n = 6 biologically independent samples. Scale bar, 100 μm). d and h mRNA expression of pro-fibrotic genes. Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.
Fig. 6 SUMOylation inhibition restores the anti-fibrotic activity of OCA. Fibrotic mice, developed by CCl4 treatment a–d or BDL operation e–h, were treated with OCA in the presence or absence of SP. n = 6 biologically independent samples within these experiments. a and e Mouse experiment procedure schemes. b and f Serum ALT and AST levels. c and g H&E, Masson, and Sirius red staining of liver sections (representative of n = 6 biologically independent samples. Scale bar, 100 μm). d and h mRNA expression of pro-fibrotic genes. Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.CC BY · PubMed Central
Fig. 7 SUMOylation inhibition restores the anti-fibrotic activity of OCA in NASH models. Mice were fed with HFHC a–d or MCD e–h diet to induce NASH-associated fibrosis and treated with OCA in the presence or absence of SP. n = 6 biologically independent samples within these experiments. a and e Mouse experiment procedure schemes. b and f Serum ALT and AST levels. c and g H&E, Masson, and Sirius red staining of liver sections (representative of n = 6 biologically independent samples. Scale bar, 100 μm). d and h mRNA expression of pro-fibrotic genes. Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.
Fig. 7 SUMOylation inhibition restores the anti-fibrotic activity of OCA in NASH models. Mice were fed with HFHC a–d or MCD e–h diet to induce NASH-associated fibrosis and treated with OCA in the presence or absence of SP. n = 6 biologically independent samples within these experiments. a and e Mouse experiment procedure schemes. b and f Serum ALT and AST levels. c and g H&E, Masson, and Sirius red staining of liver sections (representative of n = 6 biologically independent samples. Scale bar, 100 μm). d and h mRNA expression of pro-fibrotic genes. Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.CC BY · PubMed Central
Fig. 8 LD stabilization by Plin1 prevents HSC activation. a–c Plin1 overexpression precluded LD loss and HSC activation (n = 3 biologically independent samples within these experiments). a Lipids quantitation. b mRNA expression of pro-fibrotic genes. c Bodipy, Nile red, and α-SMA staining of cells (representative of n = 3 biologically independent samples). d–f Plin1 knock-down aggravated LD loss and HSC activation (n = 3 biologically independent samples within these experiments). d Lipids quantitation. e Pro-fibrotic gene mRNA levels. f Bodipy, Nile red, and α-SMA staining of cells (representative of n = 3 biologically independent samples. Scale bar, 50 μm). Results are mean ± SEM, *P < 0.05, **P < 0.01, as assessed with Student’s t-test or ANOVA.
Fig. 8 LD stabilization by Plin1 prevents HSC activation. a–c Plin1 overexpression precluded LD loss and HSC activation (n = 3 biologically independent samples within these experiments). a Lipids quantitation. b mRNA expression of pro-fibrotic genes. c Bodipy, Nile red, and α-SMA staining of cells (representative of n = 3 biologically independent samples). d–f Plin1 knock-down aggravated LD loss and HSC activation (n = 3 biologically independent samples within these experiments). d Lipids quantitation. e Pro-fibrotic gene mRNA levels. f Bodipy, Nile red, and α-SMA staining of cells (representative of n = 3 biologically independent samples. Scale bar, 50 μm). Results are mean ± SEM, *P < 0.05, **P < 0.01, as assessed with Student’s t-test or ANOVA.CC BY · PubMed Central
Fig. 9 OCA stabilizes LD and inhibits HSC activation via FXR-Plin1 pathway. a–c The effect of OCA in precluding LD loss and HSC activation depends on Plin1 (n = 3 biologically independent samples). Cells transfected with ctrl or Plin1 siRNA were treated with OCA. a Lipids quantitation. b mRNA expression of pro-fibrotic genes. c Bodipy, Nile red, and α-SMA staining of cells (representative of n = 3 biologically independent samples. Scale bar, 50 μm). d FXR antagonist and FXR knock-down abolished the upregulation of Plin1 by OCA (n = 3 biologically independent samples). e Reporter gene analysis of the Plin1 promoter in HSC-T6 cells in the absence or presence of SP, and in AML-12 cells (n = 4 biologically independent samples). f BLI analysis for the association between recombinant human FXR protein and Plin1 promoter. g ChIP analysis for the association between endogenous FXR and Plin1 promoter (n = 4 biologically independent samples). Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.
Fig. 9 OCA stabilizes LD and inhibits HSC activation via FXR-Plin1 pathway. a–c The effect of OCA in precluding LD loss and HSC activation depends on Plin1 (n = 3 biologically independent samples). Cells transfected with ctrl or Plin1 siRNA were treated with OCA. a Lipids quantitation. b mRNA expression of pro-fibrotic genes. c Bodipy, Nile red, and α-SMA staining of cells (representative of n = 3 biologically independent samples. Scale bar, 50 μm). d FXR antagonist and FXR knock-down abolished the upregulation of Plin1 by OCA (n = 3 biologically independent samples). e Reporter gene analysis of the Plin1 promoter in HSC-T6 cells in the absence or presence of SP, and in AML-12 cells (n = 4 biologically independent samples). f BLI analysis for the association between recombinant human FXR protein and Plin1 promoter. g ChIP analysis for the association between endogenous FXR and Plin1 promoter (n = 4 biologically independent samples). Results are mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ns, statistically not significant, as assessed with ANOVA.CC BY · PubMed Central
Fig. 10 SUMOylation of FXR represses Plin1 transcription. a OCA failed to upregulate the Plin1 mRNA in activated HSCs caused by CCl4 treatment, BDL operation and from NASH patients (n = 3 biologically independent samples within these experiments). b OCA failed to promote the induction of Plin1 in activated HSCs as reflected by reporter gene assays (n = 3 biologically independent samples). c SUMOylation of FXR inhibited the transcription of Plin1 (n = 3 biologically independent samples). d SP rescued the regulation of OCA on Plin1 in cultured HSCs (n = 4 biologically independent samples). e–h SP treatment restored the regulation of OCA on Plin1 in isolated HSCs from CCl4 e, BDL f, HFHC g, or MCD h mice (n = 6 biologically independent samples within these experiments). Results are mean ± SEM, *P < 0.05, **P < 0.01, and ns, statistically not significant, as assessed with ANOVA.
Fig. 10 SUMOylation of FXR represses Plin1 transcription. a OCA failed to upregulate the Plin1 mRNA in activated HSCs caused by CCl4 treatment, BDL operation and from NASH patients (n = 3 biologically independent samples within these experiments). b OCA failed to promote the induction of Plin1 in activated HSCs as reflected by reporter gene assays (n = 3 biologically independent samples). c SUMOylation of FXR inhibited the transcription of Plin1 (n = 3 biologically independent samples). d SP rescued the regulation of OCA on Plin1 in cultured HSCs (n = 4 biologically independent samples). e–h SP treatment restored the regulation of OCA on Plin1 in isolated HSCs from CCl4 e, BDL f, HFHC g, or MCD h mice (n = 6 biologically independent samples within these experiments). Results are mean ± SEM, *P < 0.05, **P < 0.01, and ns, statistically not significant, as assessed with ANOVA.CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 1 Not valid · 26 Not checked · 53 Own results and interpretations

48 more claims · 4 with their cited sources checked

Create a free account to see all 91 claims and to verify the 45 references still open.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 23
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 65 references

Cited by

See all 167

Metadata

Authors
Zhou, J., Cui, S., He, Q., Guo, Y., Pan, X., Zhang, P., Huang, N., Ge, C., Wang, G., Gonzalez, F. J., Wang, H., & Hao, H.
Affiliations
  • China Pharmaceutical University (CN)
  • National Institutes of Health (US)
Corresponding author
  • Wang, Guangji
  • Wang, Hong
  • Hao, Haiping
Venue
Nature Communications
Published
2020-01-13
Volume
11
Issue
1
Pages
240-240
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3000320209
Cited by
154
References
65
Citations by year
2026: 18 · 2025: 24 · 2024: 34 · 2023: 21 · 2022: 27 · 2021: 21 · 2020: 8
FWCI
11.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81421005, SZSM201801060, 81930109, 91429308, 2018ZX09711002, 81720108032, 81603194, 2015ZX09501010, 81530098, 81430091)
  • China Pharmaceutical University (CPU2018GF09, CPU2018GF01, SKLNMZZCX201817, 81530098)
  • China Postdoctoral Science Foundation (2017T100423, 2016M600455)
  • State Key Laboratory of Natural Medicines (SKLNMZZCX201817, SKLNMZZCX201801)
  • Sanming Project of Medicine in Shenzhen (SZSM201801060)
  • Overseas Expertise Introduction Project for Discipline Innovation (CPU2018GF09, G20582017001, CPU2018GF01)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
liver fibrosis, farnesoid X receptor, FXR agonists, obeticholic acid, SUMOylation inhibitors, hepatic stellate cell activation, nonalcoholic steatohepatitis, PLIN1, drug synergy, bile duct ligation, carbon tetrachloride-induced fibrosis
MeSH terms
Perilipin-1, Receptor, Farnesoid X-Activated, Animals, Cells, Cultured, Chenodeoxycholic Acid, Disease Models, Animal, Drug Therapy, Combination, Humans, Liver Cirrhosis, Male, Mice, Inbred C57BL, Signal Transduction, Transcriptional Activation, Treatment Outcome, Receptors, Cytoplasmic and Nuclear, Small Ubiquitin-Related Modifier Proteins, Mice, Hepatic Stellate Cells, Sumoylation, Non-alcoholic Fatty Liver Disease, Lipid Droplets

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. https://app.cochat.ai/papers/10.1038/s41467-019-14138-6
The paper
Zhou, J., Cui, S., He, Q., Guo, Y., Pan, X., Zhang, P., Huang, N., Ge, C., Wang, G., Gonzalez, F. J., Wang, H., & Hao, H. (2020). SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nature Communications. https://doi.org/10.1038/s41467-019-14138-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.